THRB and metabolic dysfunction-associated steatotic liver disease: Thyroid hormone receptor THRβ agonists, which act by increasing triacylglycerol hydrolysis and promoting lipid β‐oxidation, represent a class of treatments that are both effective and have a favorable safety profile.[40] Resmetirom, a selective THRβ agonist, is the only FDA‐approved drug to treat MASLD.[41] Alnustone also act on enhancing mitochondrial fatty acid β‐oxidation through calmodulin‐driven Ca2+ modulation, underscoring the potential of fatty acid β‐oxidation‐based therapies.